Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dipraglurant - Addex Therapeutics

Next Previous
Drug Profile

Dipraglurant - Addex Therapeutics

Alternative Names: ADX-48621; Dipraglurant-ER; Dipraglurant-IR; mGluR5-NAM

Latest Information Update: 19 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics; Sinntaxis
  • Class Alkynes; Antidepressants; Anxiolytics; Heterocyclic bicyclo compounds; Imidazoles; Muscle relaxants; Neuropsychotherapeutics; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Drug-induced dyskinesia
  • Phase II Blepharospasm; Torticollis
  • Phase I Traumatic brain injuries
  • No development reported Major depressive disorder
  • Discontinued Anxiety disorders

Most Recent Events

  • 30 Apr 2025 Addex Therapeutics collaborates with Sinntaxis AB to study dipraglurant for the treatment of brain injury recovery
  • 23 May 2024 Addex Therapeutics has patents pending for Dipraglurant composition of matter and its polymorphs
  • 23 May 2024 Addex Therapeutics has patent protection for Dipraglurant composition of matter and its polymorphs in the US, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Macedonia, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Liechtenstein, Turkey, Australia, Brazil, Canada, China, Hong Kong, Indonesia, Israel, Japan, South Korea, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa and Ukraine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top